Short-term efficacy and safety of lasmiditan, a novel 5-HT 1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

ConclusionsThis meta-analysis suggests that lasmiditan is effective for the acute treatment of migraine with a higher incidence of CNS-related adverse reactions compared with placebo. Long-term, open-label, multi-dose trials are required to verify the current findings.

http://link.springer.com/10.1186/s10194-020-01138-x

Source: The Journal of Headache and Pain - June 4, 2020 Category: Neurology Source Type: research